Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.

Pharmacogenetics and genomics - 1 Jan 2009

Taylor Matthew R G, Slavov Dobromir, Humphrey Kurt, Zhao Lan, Cockroft Jennifer, Zhu Xiao, Lavori Philip, Bristow Michael R, Mestroni Luisa, Lazzeroni Laura C

Abstract excerpt

BACKGROUND: Beta-blocker therapy has become a mainstay therapy for the over 5 million patients with chronic heart failure in the United States. Variation in clinical response to beta-blockers is a well-known phenomenon and may be because of genetic differences between patients. We hypothesized that variation in genes of the endothelin system mediate the clinical response to beta-blockers in heart failure....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Aspartic Acid Endopeptidases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endothelin-1

Share to Endothelins

Share to Heart Failure

Share to Metalloendopeptidases

Share to Propanolamines

Share to Receptors, Endothelin

Source

Open in PubMed Open full text

Identifiers

PMID: 18953265
DOI: 10.1097/FPC.0b013e328317cc57
PMCID: PMC3035051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.PMID 18953265Read ↗

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Semantic proximity Read ↗

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Semantic proximity Read ↗

Heart failure pharmacogenetics: past, present, and future.Semantic proximity Read ↗

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read ↗

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsSemantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.Semantic proximity Read ↗

Emerging role of pharmacogenomics in heart failure.Semantic proximity Read ↗

Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.Semantic proximity Read ↗

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Semantic proximity Read ↗

Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.